Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dare Bioscience Inc DARE

Healthcare Biotechnology
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial... see more

Recent & Breaking News (NDAQ:DARE)

Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update

GlobeNewswire August 12, 2020

Daré Bioscience CEO to Participate in Maxim Group's Leading Innovators in Women's Health Virtual Conference

GlobeNewswire August 6, 2020

Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020

GlobeNewswire August 5, 2020

Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Symptoms

GlobeNewswire July 27, 2020

Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction

GlobeNewswire June 24, 2020

Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis

GlobeNewswire June 17, 2020

Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive

GlobeNewswire June 15, 2020

Daré Bioscience Announces Participation in BIO Digital 2020

GlobeNewswire June 4, 2020

Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update

GlobeNewswire May 14, 2020

Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré's Novel Pipeline of Women's Health Programs

GlobeNewswire May 11, 2020

Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020

GlobeNewswire May 7, 2020

Daré Bioscience CEO to Participate in Maxim Group's Infectious Disease Virtual Conference

GlobeNewswire April 28, 2020

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

GlobeNewswire April 23, 2020

Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene®

GlobeNewswire April 1, 2020

Daré Bioscience Reports 2019 Financial Results and Provides a Company Update

GlobeNewswire March 30, 2020

Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020

GlobeNewswire March 24, 2020

Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis

GlobeNewswire March 10, 2020

Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder

GlobeNewswire March 9, 2020

Daré Bioscience to Present at the Cowen 40th Annual Health Care Conference

GlobeNewswire February 27, 2020

Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO

GlobeNewswire February 12, 2020